GTS Securities’s TG Therapeutics TGTX Stock Holding History

GTS Securities’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,139	Closed	-$237K	–	1856
2026 Q1	$237K	Buy	+7,139	New	+$213K	0.01%	1250
2024 Q4	–	Sell	-224,875	Closed	-$5.26M	–	3823
2024 Q3	$5.26M	Sell	224,875 -26,910	-11%	-$588K	0.01%	860
2024 Q2	$4.48M	Buy	251,785 +8,274	+3%	+$132K	0.01%	934
2024 Q1	$3.7M	Sell	243,511 -167,260	-41%	-$2.66M	0.01%	1065
2023 Q4	$7.02M	Buy	410,771 +200,805	+96%	+$2.33M	0.01%	795
2023 Q3	$1.76M	Buy	+209,966	New	+$2.93M	﹤0.01%	1613

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

GTS Securities's TGTX Position: Q2 2026 in Review

GTS Securities sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 7,139 shares — an estimated $237K sold.

GTS Securities first reported a position in TGTX in Q3 2023 and held it in 6 quarters. The position peaked at $7.02M in Q4 2023. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

GTS Securities reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
GTS Securities sold 7,139 TG Therapeutics shares in Q2 2026, an estimated $237K.
GTS Securities first reported a position in TG Therapeutics in Q3 2023 and held it in 6 quarters.
GTS Securities's TG Therapeutics position peaked at $7.02M in Q4 2023.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.